Synchron Raises $200 Million to Advance Its Brain-Computer Interface for Paralysis
Synchron has secured $200 million in a Series D funding round, which it plans to use to expand its operations and accelerate the commercialization of its non-surgical brain-computer interface (BCI) for individuals with paralysis.
Investors and Partners
The round was led by Double Point Ventures and included participation from existing backers such as Arch Ventures, Khosta Ventures, Bezos Expeditions, NTI, and Metis. Additional investors included the Australian National Reconstruction Fund, T.Rx Capital, the Qatar Investment Authority, K5 Global, Protocol Labs, and IQT.
Market Context
This funding brings the New York-based medtech company’s total capital to $345 million, marking a strong momentum for the BCI sector.
Earlier this week, Precision Neuroscience, another BCI developer focused on paralysis, announced a partnership with SCI Ventures, a fund backed by the Christopher & Dana Reeve Foundation, to advance its Layer 7 Cortical Interface.
Last month, a study showed that Science Corp.’s PRIMA BCI retinal implant restored partial vision in patients with severe age-related macular degeneration.
Author Summary
Synchron’s $200 million boost underscores growing investor confidence in non-surgical brain-computer interfaces aimed at improving the quality of life for people with paralysis.